Natera reported second quarter 2026 financial results with total revenues of $752.8 million, a 37.7% increase from the prior year period. The company processed approximately 1,043,900 tests, including roughly 296,700 oncology tests, while achieving a gross margin of 64.5%. Natera raised its full-year 2026 revenue guidance midpoint by $100 million to $2.85 billion–$2.91 billion and reported a net loss of $67.0 million, or ($0.47) per diluted share. The company operates in the precision medicine and genetic testing industry.
